ASYMCHEM LAB.(TIAN.)H YC1 (7K90) - Total Assets
Based on the latest financial reports, ASYMCHEM LAB.(TIAN.)H YC1 (7K90) holds total assets worth €20.70 Billion EUR (≈ $24.21 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ASYMCHEM LAB.(TIAN.)H YC1 - Total Assets Trend (2021–2025)
This chart illustrates how ASYMCHEM LAB.(TIAN.)H YC1's total assets have evolved over time, based on quarterly financial data. Also see 7K90 market cap overview for the company's overall valuation and market capitalisation.
ASYMCHEM LAB.(TIAN.)H YC1 - Asset Composition Analysis
Current Asset Composition (December 2025)
ASYMCHEM LAB.(TIAN.)H YC1's total assets of €20.70 Billion consist of 56.7% current assets and 43.3% non-current assets. Review total liabilities of ASYMCHEM LAB.(TIAN.)H YC1 to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 31.2% |
| Accounts Receivable | €1.95 Billion | 9.6% |
| Inventory | €1.47 Billion | 7.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €421.80 Million | 2.1% |
| Goodwill | €146.18 Million | 0.7% |
Asset Composition Trend (2021–2025)
This chart illustrates how ASYMCHEM LAB.(TIAN.)H YC1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest ASYMCHEM LAB.(TIAN.)H YC1 stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ASYMCHEM LAB.(TIAN.)H YC1's current assets represent 56.7% of total assets in 2025, a decrease from 68.0% in 2021.
- Cash Position: Cash and equivalents constituted 31.2% of total assets in 2025, down from 41.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 9.6% of total assets.
ASYMCHEM LAB.(TIAN.)H YC1 Competitors by Total Assets
Key competitors of ASYMCHEM LAB.(TIAN.)H YC1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Hugel Inc
KQ:145020
|
Korea | ₩1.13 Trillion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Beijing Scitop Bio Tech Co Ltd
SHE:300858
|
China | CN¥2.03 Billion |
ASYMCHEM LAB.(TIAN.)H YC1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.69 | 7.16 | 5.62 |
| Quick Ratio | 4.91 | 6.39 | 5.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €9.67 Billion | €9.59 Billion | €8.74 Billion |
ASYMCHEM LAB.(TIAN.)H YC1 - Advanced Valuation Insights
This section examines the relationship between ASYMCHEM LAB.(TIAN.)H YC1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.70 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 5.1% |
| Total Assets | €20.28 Billion |
| Market Capitalization | $478.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values ASYMCHEM LAB.(TIAN.)H YC1's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: ASYMCHEM LAB.(TIAN.)H YC1's assets grew by 5.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for ASYMCHEM LAB.(TIAN.)H YC1 (2021–2025)
The table below shows the annual total assets of ASYMCHEM LAB.(TIAN.)H YC1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €20.28 Billion ≈ $23.71 Billion |
+5.13% |
| 2024-12-31 | €19.29 Billion ≈ $22.55 Billion |
-2.42% |
| 2023-12-31 | €19.77 Billion ≈ $23.11 Billion |
+8.38% |
| 2022-12-31 | €18.24 Billion ≈ $21.32 Billion |
+20.34% |
| 2021-12-31 | €15.16 Billion ≈ $17.72 Billion |
-- |
About ASYMCHEM LAB.(TIAN.)H YC1
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more